Hanmi Group, which has been accelerating its global market expansion following its transition to a new professional management system, is set to revamp its compensation structure to attract top-tier international talent.
On August 1, Hanmi Science, the holding company of Hanmi Group, and Hanmi Pharm, its core operating subsidiary, announced the introduction of a stock-based performance incentive program for employees. The program aims to instill a genuine sense of ownership among staff and strengthen motivation toward achieving the company’s mid- and long-term goals.
This strategic decision is part of Hanmi’s broader efforts to attract highly competitive talent and establish a global-standard performance reward system, thereby fostering a more motivated workforce and reinforcing a performance-driven organizational culture.
The new stock-based compensation system will be primarily divided into two methods: RSA (Restricted Stock Award) and RSU (Restricted Stock Unit).
Under RSA, employees can receive a portion of their existing performance incentives (PI) in the form of company stock. Depending on semi-annual performance evaluations, employees may opt to receive between 50% and 100% of their PI as stock. The company will also compensate for any potential stock price declines, reducing employee risk.
RSU offers long-term rewards linked to the company’s value growth. Employees contributing to significant increases in sales or profits, drug approvals, or technology exports—factors that substantially enhance corporate value—may be granted RSUs worth up to 100% of their annual salary, distributed in a differentiated manner based on performance.
This program will apply to employees working at key affiliates such as Hanmi Science, Hanmi Pharm, online pharmacy subsidiary Online Pharm, and Hanmi Fine Chemicals, a specialty API manufacturer. Major shareholders are excluded from participation.
Hanmi expects that this new compensation system will enable both the company and its employees to focus on shared goals and jointly achieve sustainable growth. The final details will be confirmed after approval by the board of directors.
Kim Jae-kyo of Hanmi Science emphasized, “In the fiercely competitive pharmaceutical and biotech industry, a performance-based compensation system is essential for securing future competitiveness." He added, “Through this initiative, we aim to attract global top talent and foster a culture where all employees take ownership, ultimately realizing sustainable corporate value.”
